- Q4 2023 Phathom Pharmaceuticals Inc Earnings Call TranscriptMar 07, 2024$9.09 (-6.58%)Earnings
- Phathom Pharmaceuticals Inc to Discuss The FDA Approval TranscriptNov 02, 2023
- Phathom Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Phathom Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 18, 2023
- Phathom Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
- Phathom Pharmaceuticals Inc Conference call on the PHALCON-EE Trial Results TranscriptOct 18, 2021
- Phathom Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2021
- Phathom Pharmaceuticals Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- Phathom Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 21, 2021
- Phathom Pharmaceuticals Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Phathom Pharmaceuticals Inc Phase 3 PHALCON-HP Results Corporate Call TranscriptApr 29, 2021
- Phathom Pharmaceuticals Inc Corporate Analyst Meeting TranscriptDec 14, 2020
- Phathom Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2020
- Phathom Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Phathom Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 21, 2020
Phathom Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. I'm Paul Choi, the Mid-cap Biotechnology Analyst at Goldman Sachs, and we'll continue with our next session here, which is with Phathom Pharmaceuticals. From the Management side, we are very happy to have Terrie Curran, the CEO. Also on the line with us is Azmi Nabulsi, who is the COO.
As with prior sessions, what we'll do is let Terrie kick it off with some opening remarks and an introduction to the company. After that, we'll go into the Q&A portion of the session. (Operator Instructions)
And that -- with that, I'll turn it over to Terrie for an overview of Phathom. Terrie?
Thank you, Paul, and thank you for inviting us today, and hello, everybody. As Paul said, my name is Terrie Curran, I'm the CEO of Phathom. Phathom is a clinical stage company, our lead asset is vonoprazan, and vonoprazan is a potassium competitive acid blocker. The company was formed very
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)